Cypress, CA

Phase 1 Clinical Trial Unit

Our largest clinical pharmacology unit is designed specifically for Phase 1 clinical trials and is uniquely positioned to meet your high-volume enrollment needs.

 Cypress, CA

With 75,000 square feet and over 180 beds, the Cypress, CA, Phase 1 unit is the largest WCCT location. This clinical pharmacology unit is dedicated to early clinical development studies and can provide housing for long-term, in-house trials, and services for both normal healthy volunteers (NHV) and large ethnobridging clinical trials.

This Phase 1 unit is uniquely positioned between the Orange County and Los Angeles areas (Los Angeles County – 9.3 MM, Orange County – 2.7 MM, Riverside/San Bernardino Counties – 3.1 MM), giving it the ability to strategically recruit from a diverse ethnic population of over 15 million.

Many healthy volunteers are also available for recruitment from multiple universities nearby. To ensure the success of your study’s enrollment, the Cypress Phase 1 clinical trial unit’s active outreach team aids community clinical research education and augments our overall patient recruitment efforts.

Other Notable Safety Features

  • Only Phase 1 clinical trial unit to be authorized as an American Heart Association training site
  • 130+ employees trained for Emergency Response situations
  • On-site CLIA-Certified Safety Reference Laboratory capable of conducting hundreds of clinically-significant tests
  • Peripheral Blood Mononuclear Cell (PBMC) processing capabilities
  • USP 797-certified sterile room for parenteral drug preparation
Key Features/Capabilities:
Special procedures performed:
  • Pulmonary function testing
  • Bronchoscopy
  • Biopsies
  • Glucose monitoring
  • IV infusion
  • Subcutaneous and intramuscular injections
  • Skin blister
  • X-rays
  • MRIs
  • Vaginal ultrasounds and pap smears
  • Multilingual staff to provide comfortable accommodation and cultural sensitivity for ethnic sensitivity studies
  • Bio fluid collection:
    • Stool
    • Sputum
    • Semen
    • 24-hour urine collection
    • Serial CSF collection and processing
Studies Performed:
  • Ethnobridging/Asian bridging studies
  • BA/BE
  • PK
  • FIH
  • Drug delivery (including devices)
  • Food effect
  • Cardiac safety
  • TQT
  • Serial ECGs
  • Telemetry
  • Atomic clocks and watches for time synchronization
  • Six refrigerated centrifuges
  • 12+ ECG machines
  • Three -70º C freezers
  • Multiple -20º C freezers, several 2-8ºC refrigerators
  • Treadmill equipment
  • Slit lamps
  • Goldmann and Perkins applanation tonometers
  • Pupillometers
  • Telemetry and holter-capable
  • Stadiometers, crash carts
  • Nitric oxide machine
  • Platelet aggregometry lab
  • Multiple spirometry units

Investigator Profile

Dr. Apinya Vutikullird, D.O.

As a board-certified family physician with over ten years of clinical research experience with WCCT, Dr. Apinya Vutikullird, D.O., has been a principle investigator on over 125 studies and a subinvestigator on over 250 studies. These studies have spanned many specialty therapeutic areas ranging from diabetes, pediatrics, allergy and asthma, hepatitis C, glaucoma, renal failure, postmenopausal, vaccines, alzheimer’s, muscular dystrophy, CHF and Japanese/Chinese/Korean bridging. The types of studies are also diverse – from thorough TQT trials, telemetry/PFT/24hours CSF/stool/sputum/semen collection, medical device, FIH (with Sentinel groups), biologics/human monoclonal immunoglobulin antibody, multiple-days IV infusion, SAD, MAD, BA/BE, food effects, and DDI. As the Medical Director of WCCT, she coordinates all the studies at the various WCCT sites, as well as all of WCCT’s investigators and community consultants/partners. Dr. Vutikullird has served as a medical monitor and consultant on numerous studies over her long career. She also leads safety committees, supports data review and trains and oversees clinical staff.


Stay up-to-date on clinical research news and developments.


Careers that put you at the forefront of medical breakthroughs.


The blog delivers industry-related developments and announcements regarding expanded clinical services.